Benzinga | Nov 23, 2020 06:27AM EST

HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $33

HC Wainwright & Co. maintains Spero Therapeutics (NASDAQ:SPRO) with a Buy and raises the price target from $28 to $33.